Early treatment with, and time receiving, first disease-modifying antirheumatic drug predicts long-term function in patients with inflammatory polyarthritis

Tracey M. Farragher, Mark Lunt, Bo Fu, Diane Bunn, Deborah P. M. Symmons

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)


Objectives To investigate the influence of early disease-modifying antirheumatic drug (DMARD) treatment on long-term functional outcome in patients with recent-onset inflammatory polyarthritis (IP), and the impact of the duration of first and subsequent DMARD treatment. Methods 642 subjects from a primary care registry of patients with new-onset IP, recruited 1990–4, were followed up for 10 years. Mean change in Health Assessment Questionnaire (HAQ) scores between baseline and 10 years were compared by time to, and time receiving, first DMARD treatment and total time receiving treatment, using linear regression. Adjustment for time-dependent confounders and censoring was performed using marginal structural weights. Results When adjusted for baseline and subsequent disease severity, those treated early (
Original languageEnglish
Pages (from-to)689-695
Number of pages7
JournalAnnals of the Rheumatic Diseases
Issue number4
Publication statusPublished - 2010

Cite this